Oragenics to Receive European Patent for Its IVIAT(TM) Biomarker Technology

Link: Oragenics to Receive European Patent for Its IVIAT(TM) Biomarker Technology.

IVIAT(TM) is a unique discovery platform designed to identify genes of pathogenic bacteria that are specifically present when humans have infections. Dr. Robert Zahradnik, Oragenics' President and CEO, stated, "The IVIAT(TM) technology has already proven its ability to identify novel targets for such infectious agents as Vibrio cholerae (cholera), Escherichia coli (E. coli) and Pseudomonas aeruginosa, which causes infections in persons with compromised immune systems in addition to causing one out of ten hospital acquired infections.